AI in R&D Platforms

Biotech Licensing and Collaborations

Artificial Intelligence Meets Pharmacovigilance

Data Governance in Life Sciences

Resilient by Design

EDITORIAL SECTION

STRATEGY

Strategic Positioning for M&A

The biotechnology sector is characterised by a constant influx of small highly specialised companies

RESEARCH DEVELOPMENT

Cytiva Laboratory capsule filters

Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling

CLINICAL TRIALS

Virtual Clinical Trials

Virtual digital and decentralized are all descriptions of the novel ways that using technology changes

Bio Pharma

Biosimilars and Biobetters

Biosimilars are biologic medical products that are essentially identical to an original product manufactured

MANUFACTURING

Transformative Convergence of AI in Pharmaceutical Manufacturing

The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by

Information Technology

Transformative Impact of Artificial Intelligence on Clinical Trials

Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries

EXPERT Talk

Sustainable Innovation in Biopharma: Aligning Therapeutic Progress with Environmental Responsibility

To genuinely align RD with environmental responsibility biopharma organisations must embrace systemic structural and cultural transformations

Advisory Board

Victor M. Diaz Perez

Kishore Hotha

Joab Williamson

Scott M. Wheelwright

Tamara Miller

Juris Hmelnickis

David Contorno

Svetlana Busiguina

Eiman Shafa

Nigel Cryer FRSC

Hector Alejandro Andonie

Josipa Ljubicic

KNOWLEDGE BANK

Articles

Applying CPCA: A Risk Based Framework for Nitrosamine Control in Pharmaceuticals

NNitrosamines are a structurally diverse class of potent mutagenic carcinogens formed when nitrosating species react with amines often via hydroxylation to DNA reactive intermediates Even at trace levels long term exposure in chronically administered medicines can translate into a measurable incremental lifetime cancer risk The discovery of nitrosamines in valsartan and other sartan products was...

Techno Trends

Case Western Reserve Scientists Discover Novel Molecular Target for Parkinson’s Disease

Researchers at Case Western Reserve University have discovered a new biochemical pathway that could lead to treatments targeting the underlying causes of Parkinsons disease

Projects

PharmaEssentia Invests $46M to Expand U.S. Manufacturing Footprint for BESREMi®

PharmaEssentia Corporation has announced plans to establish a new wholly owned manufacturing subsidiary in Puerto Rico The US million investment aims to expand the production of BESREMi

Research Insights

Controllable protein design via autoregressive direct coupling analysis conditioned on principal components

We present FeatureDCA a statistical framework for protein sequence modeling and generation that extends Direct Coupling Analysis DCA

White Papers

Accelerating In-Vitro Antibody Discovery with Artificial Intelligence

Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities

press releasesRead more...

The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

When we discuss bacterial infections we often think of exotoxinsthose soluble proteins actively secreted by bacteriawhile overlooking endotoxins which are more insidious but equally dangerous Endotoxins are not released by bacteria rather they are natural components residing in the bacterial

Ramarketing acquires US market research firm ISR

Strategic life sciences marketing agency ramarketing has completed the acquisition of ISR Market Research a specialist agency based in North Carolinas Research Triangle Park RTP one of the largest pharmaceutical and biopharma hubs in North America

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Affinia an innovative gene therapy company with a pipeline of firstinclass andor bestinclass adenoassociated virus AAV gene therapies initially for devastating cardiovascular diseases

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients

Vasomune Therapeutics Inc a clinicalstage biopharmaceutical company today announced US Food and Drug Administration FDA clearance of the Investigational New Drug IND application to develop Pegevongitide AV